Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date β€” because we believe great analysis should be held accountable.

AllAAOIACADADMAAGIOALMSALMUALTSAPGEAUPHAVAVBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTRIGCTGOOGGPCRHALOHIMSHOODHWMIRENIVVDKALAKALVLENZLEVILITELRMRLULULUNRMDGLMESOMOHMTCHMUMVSTNBISNKENRIXNVAXOKUROLMAONCOSCRPHATPLRXPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHAUNHVEONVORWVEXFORZLAB
Celcuity Inc. (CELC) presents a high-risk, high-reward investment opportunity driven by its lead asset, gedatolisib. This pan-PI3K/mTOR inhibitor demonstrated unprecedented efficacy in the Phase 3 VIKTORIA-1 trial for PIK3CA wild-type HR+/HER2- advanced breast cancer, showing a 76% reduction in progression risk and 7.3-month PFS improvement. The transformative data triggered a stock surge and enabled a strategic $248.7 million capital raise, extending the cash runway through key catalysts. While the IV administration route and single-asset dependency pose significant commercial and clinical risks, the potential for gedatolisib to become a new standard of care in a multi-billion dollar market supports a ​​Speculative Buy​​ recommendation.

Celcuity Inc. (CELC): An In-Depth Analysis of a Paradigm-Shifting Oncology Asset

2025-07-31Change from report: +199.1%1M: +36.8%3M: +97.0%

Celcuity Inc. (CELC) presents a high-risk, high-reward investment opportunity driven by its lead asset, gedatolisib. This pan-PI3K/mTOR inhibitor demonstrated unprecedented efficacy in the Phase 3 VIKTORIA-1 trial for PIK3CA wild-type HR+/HER2- advanced breast cancer, showing a 76% reduction in progression risk and 7.3-month PFS improvement. The transformative data triggered a stock surge and enabled a strategic $248.7 million capital raise, extending the cash runway through key catalysts. While the IV administration route and single-asset dependency pose significant commercial and clinical risks, the potential for gedatolisib to become a new standard of care in a multi-billion dollar market supports a ​​Speculative Buy​​ recommendation.